Inserire di nuova l’introduzione
NCT03762122 | SNCTP000003239

SAKK 19/18
Rogaratinib zur Behandlung von Patienten mit fortgeschrittenem, nicht-kleinzelligem Lungenkrebs (Plattenepithelkarzinom) und hoher Produktion von Rezeptoren für den Wachstumsfaktor FGF.

Base di dati: BASEC (Importata da 24.05.2020), WHO (Importata da 22.03.2020)
Cambiato: 20.04.2020
Categoria di malattie: Lungenkrebs

Descrizione riassuntiva della sperimentazione (Fonte di dati: BASEC)

Die Studie untersucht, ob und wie gut die Prüfsubstanz Rogaratinib bei Patienten mit einem fortgeschrittenen Plattenepithelkarzinom der Lunge («squamous cell lung cancer, SQCLC») wirkt und wie verträglich resp. sicher diese Substanz ist.

Malattie studiate (Fonte di dati: BASEC)

Fortgeschrittener, nicht-kleinzelliger Lungenkrebs (Plattenepithelkarzinom)

Health conditions (Fonte di dati: WHO)

Squamous-cell Non-small Cell Lung Cancer

Malattia rara (Fonte di dati: BASEC)

No

Interventi esaminati (p. es. medicamento, terapia, campagna) (Fonte di dati: BASEC)

Das Studienmedikament Rogaratinib wird zweimal täglich in Tablettenform eingenommen (je 600 mg pro Dosis, also insgesammt 1200 mg pro Tag). Diese Behandlung wird so lange fortgeführt, bis die Krebskrankheit erneut fortschreitet, die Behandlung abgebrochen werden muss (z.B. wegen Nebenwirkungen) oder der Teilnehmer die Behandlung nicht mehr weiterführen möchte.
Alle Teilnehmer der Studie werden lebenslang von den Studienärzten nachkontrolliert.

Interventions (Fonte di dati: WHO)

Drug: Rogaratinib

Criteri per la partecipazione alla sperimentazione (Fonte di dati: BASEC)

An der Studie können Personen teilnehmen, die an einem Plattenepithelkarzinom der Lunge leiden, und deren Tumorzellen übermässig stark FGFR produzieren.
Mindestens eine Behandlung des Plattenepithelkarzinoms muss schon vor Studienbeginn durchgeführt worden sein (z.B. Chemotherapie).
Die teilnehmenden Personen müssen damit einverstanden sein, dass ihr Tumorgewebe für zusätzliche studienspezifische Forschungsprojekte untersucht wird.

Criteri di esclusione (Fonte di dati: BASEC)

Personen, die in den drei Wochen vor geplantem Studienbeginn eine Chemo- oder Immuntherapie erhalten haben, oder die bestimmte Medikamente einnehmen, dürfen an dieser Studie nicht teilnehmen.
Personen, die an einer Erkrankung der Netzhaut im Auge leiden und
Frauen, die schwanger werden möchten, schwanger sind oder stillen, können ebenfalls nicht an der Studie teilnehmen.

Inclusion/Exclusion Criteria (Fonte di dati: WHO)


Inclusion Criteria:

- Written informed consent according to Swiss law and ICH-GCP regulations before
registration and prior to any trial specific procedures including screening
procedures. Informed consent for trial entry must be offered only after positive
results of individual FGFR testing has been received.

- Histologically or cytologically confirmed diagnosis of locally advanced or metastatic
NSCLC (from inoperable stage IIIB to stage IV according to the 8th edition of the
American Joint Commission on Cancer TNM staging system) with squamous-cell or
predominantly squamous-cell histology (referred to SQCLC).

- Archival or fresh tumor biopsy specimen for FGFR (subtypes 1-3) mRNA expression
testing available. Acceptable samples include core needle biopsies for deep tumor
tissue (minimum three cores) or excisional, incisional, punch, or forceps biopsies for
cutaneous, subcutaneous, or mucosal lesions.

- High FGFR1-3 mRNA expression levels based on central analysis of archival or fresh
tumor biopsy specimen (high expression defined as = 1 FGFR isoform with RNAscope score
of 3 or 4).

- Measurable or evaluable disease (according to RECIST v1.1). Previously irradiated
lesions should not be counted as target lesions unless there has been demonstrated
progression in the lesion since radiotherapy before enrolment and no other lesions are
available for selection as target lesions.

- Patient failed standard systemic therapy for locally advanced or metastatic disease
(1-3 prior chemotherapy regimens and at least 1 immune checkpoint inhibitor
(combination allowed)).

- Patients with known brain metastases must have undergone definitive treatment (surgery
and/or radiation) at least 2 weeks prior to registration and must be clinically stable
(no requirement of steroids and no worsening neurological deficits for 2 weeks prior
registration).

- Patients with a prior malignancy and treated with curative intention are eligible if
treatment of that malignancy was completed at least 2 years before registration and
the patient has no evidence of disease at registration. Less than 2 years is
acceptable for malignancies with low risk of recurrence and/or no late recurrence.

- Known human immunodeficiency virus (HIV)-infected patients who are healthy and have a
low risk of AIDS-related outcomes are eligible, if,

- CD4+ T-cell counts are = 350 cells/uL

- No history of AIDS-defining opportunistic infection within past 12 months

- Patient agrees to concomitant antiretroviral therapy (ART) if not currently on
ART, or is on ART for ? 4 weeks and has a HIV viral load ? 400 copies/mL.

- Age = 18 years.

- WHO performance status 0-2.

- Adequate bone marrow function: absolute neutrophil count (ANC) = 1.5 x 109/L1,
platelet count = 100 x 109/L2, hemoglobin = 90 g/L2

1. without granulocyte colony-stimulating factor support within 2 weeks before the
first administration of trial treatment

2. without transfusion or erythropoietin within 2 weeks before the first
administration of trial treatment

- Adequate hepatic function: total bilirubin = 1.5 x ULN (= 3 x ULN for patients with
known Gilbert syndrome), ALT and AST = 2.5 x ULN (= 5 x ULN for patients with liver
involvement of their cancer).

- Adequate renal function: estimated glomerular filtration rate (eGFR) > 30
mL/min/1.73m2 according to the CKD-EPI (Chronic Kidney Disease Epidemiology
Collaboration) abbreviated formula.

- Adequate pancreatic function: lipase = 2 x ULN.

- Women with childbearing potential are using highly effective contraception, are not
pregnant or lactating and agree not to become pregnant during trial treatment and
during 5 months thereafter. A negative urine or serum pregnancy test before
registration is required for all women with child-bearing potential.

- Men agree not to donate sperm or father a child. Men without a vasectomy and with a
partner of childbearing potential must agree to use condoms during trial treatment and
during 5 months thereafter.

- Patient is able and willing to swallow the trial IMP as whole tablet.

- Patient consents to the mandatory translational research projects with biopsied tumor
material.

Exclusion Criteria:

- Symptomatic untreated brain metastases or leptomeningeal disease.

- Previous treatment with anti-FGFR directed therapies (e.g. receptor tyrosine kinase
inhibitors including rogaratinib or FGFR-specific antibodies).

- Chemotherapy, or radiotherapy, or immunotherapy, or small molecule drugs within 3
weeks (1 week for palliative radiotherapy) prior to registration.

- Other investigational medicinal products within 4 weeks prior registration.

- Major surgery within 2 weeks prior registration.

- Concomitant use of other anti-cancer drugs or radiotherapy except for local pain
control.

- Concomitant therapies that are known to increase serum phosphate levels (i.e.
antacids, laxatives oral/rectal, oral phosphate binders, potassium phosphate) and that
cannot be discontinued or switched to a different medication before trial entry.

- Use of strong inhibitors of CYP3A4 and strong inducers of CYP3A4 within 2 weeks prior
registration or during trial treatment.

- History or current condition of an uncontrolled cardiovascular disease including any
of the following conditions:

- Congestive heart failure (CHF) NYHA Class 2 or greater, unstable angina (symptoms
of angina at rest).

- New-onset angina (within last 3 months prior registration).

- Myocardial infarction (MI) within past 6 months prior registration.

- Unstable cardiac arrhythmias requiring anti-arrhythmic therapy. Patients with
arrhythmia not requiring therapy or under control with anti-arrhythmic therapy
are eligible.

- Patients with known coronary artery disease, congestive heart failure not meeting
the above criteria, must be on a stable medical regimen that is optimized in the
opinion of the treating physician, in consultation with a cardiologist if
appropriate.

- Symptomatic arterial hypotension.

- Current diagnosis of any retinal disorders including retinal detachment, retinal
pigment epithelial detachment (RPED), serous retinopathy or retinal vein occlusion.

- Current evidence of endocrine alteration of calcium phosphate homeostasis (e.g.

Altri dati sulla sperimentazione nel registro primario dell’OMS

https://clinicaltrials.gov/show/NCT03762122

Altri dati sulla sperimentazione dalla banca dati dell’OMS (ICTRP)

http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT03762122

Altre informazioni sulla sperimentazione

Data di registrazione della sperimentazione

30.11.2018

Inserimento del primo partecipante

25.07.2019

Stato di reclutamento

Recruiting

Titolo scientifico (Fonte di dati: WHO)

Fibroblast Growth Factor Receptor (FGFR) Inhibitor Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) Overexpressing FGFR mRNA. A Multicenter, Single Arm Phase II Trial

Tipo di sperimentazione (Fonte di dati: WHO)

Interventional

Disegno della sperimentazione (Fonte di dati: WHO)

Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Fase (Fonte di dati: WHO)

Phase 2

Punti finali primari (Fonte di dati: WHO)

Progression-free survival (PFS) at 6 months

Punti finali secondari (Fonte di dati: WHO)

Objective response (OR);Progression-free survival (PFS);Overall survival (OS);Adverse events (AEs)

Contatto per informazioni (Fonte di dati: WHO)

Please refer to primary and secondary sponsors

Siti di esecuzione della sperimentazione

Siti di esecuzione in Svizzera (Fonte di dati: BASEC)

Baden, Basel, Bellinzona, Bern, Bruderholz, Brugg, Chur, Freiburg, Genf, Liestal, St Gallen, Winterthur

Paesi di esecuzione (Fonte di dati: WHO)

Switzerland

Contatto per maggiori informazioni sulla sperimentazione

Dati della persona di contatto in Svizzera (Fonte di dati: BASEC)

SAKK, Gilles Godard
+41 31 389 91 91
trials@sakk.ch

Contatto per informazioni generali (Fonte di dati: WHO)

Alfredo Addeo, MD;Gilles Godar
University Hospital, Geneva
+41 31 389 91 91
trials@sakk.ch

Contatto per informazioni scientifiche (Fonte di dati: WHO)

Alfredo Addeo, MD;Gilles Godar
University Hospital, Geneva
+41 31 389 91 91
trials@sakk.ch

Responsabile della sperimentazione

Sponsor principale (Fonte di dati: WHO)

Swiss Group for Clinical Cancer Research

Altri numeri di identificazione delle sperimentazioni

BASEC ID (Fonte di dati: BASEC)

2018-02355

Secondary ID (Fonte di dati: WHO)

SAKK 19/18